TNGX Tango Therapeutics, Inc.
Tango Therapeutics, Inc. (TNGX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $961.5K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Newcomb Jessica 3 fills | Principal Accounting Officer | Sell 10b5-1 | 8,200 | $24.22 | $198.6K | 66,621 −11% of holding | |
| Crystal Adam 2 fills | President, R&D | Sell 10b5-1 | 27,000 | $27.24 | $735.5K | 137,476 −16.4% of holding | |
| Crystal Adam 2 fills | President, R&D | Sell 10b5-1 | 27,000 | $29.59 | $798.9K | 123,114 −18% of holding | |
| Crystal Adam 2 fills | President, R&D | Sell 10b5-1 | 27,000 | $22.87 | $617.6K | 136,603 −16.5% of holding | |
| Crystal Adam 2 fills | President, R&D | Sell 10b5-1 | 27,000 | $21.23 | $573.1K | 116,843 −18.8% of holding | |
| Crystal Adam | President, R&D | Sell 10b5-1 | 38,460 | $25.00 | $961.5K | 112,622 −25.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.